Acrivon Therapeutics (ACRV) Profit After Tax (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Profit After Tax of -$19.0 million for Q1 2026, up 3.34% year-over-year from -$18.4 million in Q1 2025, and down 2.1% quarter-over-quarter from -$18.6 million in Q4 2025.
Acrivon Therapeutics (ACRV) Profit After Tax (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Profit After Tax for 6 consecutive years, with -$19.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 3.34% year-over-year to -$19.0 million; the TTM figure through Mar 2026 stood at -$76.9 million (up 8.17% YoY), while the FY2025 annual figure was -$77.9 million, up 3.29% from the prior year.
- Profit After Tax declined to -$19.0 million in Q1 2026 per ACRV's latest filing, from -$18.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$5.8 million in Q2 2022 and bottomed at -$22.8 million in Q4 2024.
- Historically, Profit After Tax has averaged -$15.8 million across 5 years, with a median of -$18.2 million in 2025.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 276.97% — and 2025, when it grew 18.77%.
- Acrivon Therapeutics' Profit After Tax stood at -$9.0 million in 2022, then sank by 114.95% to -$19.3 million in 2023, then declined by 18.52% to -$22.8 million in 2024, then increased by 18.31% to -$18.6 million in 2025, then fell by 2.1% to -$19.0 million in 2026.
- Business Quant data shows ACRV's Profit After Tax at -$19.0 million in Q1 2026, -$18.6 million in Q4 2025, and -$18.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.00 Mn |
| Mar 31, 2026 | -19.04 Mn |
| Dec 31, 2025 | -18.65 Mn |
| Sep 30, 2025 | -18.23 Mn |
| Jun 30, 2025 | -21.01 Mn |
| Mar 31, 2025 | -19.70 Mn |
| Dec 31, 2024 | -22.83 Mn |
| Sep 30, 2024 | -22.44 Mn |
| Jun 30, 2024 | -18.80 Mn |
| Mar 31, 2024 | -16.49 Mn |
| Dec 31, 2023 | -19.26 Mn |
| Sep 30, 2023 | -14.47 Mn |
| Jun 30, 2023 | -13.91 Mn |
| Mar 31, 2023 | -12.76 Mn |
| Dec 31, 2022 | -8.96 Mn |
| Sep 30, 2022 | -9.20 Mn |
| Jun 30, 2022 | -5.82 Mn |
| Mar 31, 2022 | -7.22 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -2.44 Mn |